Morphic Holding, Inc.

Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation

Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Morphic Holding, Inc. (NASDAQ: MORF), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Morhpic securities? If you purchased securities and suffered significant losses on your investment, join our investigation now:

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.
Name(Required)
Max. file size: 256 MB.
Would you like to receive future case and securities updates from Johnson Fistel, LLP via email?(Required)
Would you like to receive information about Johnson Fistel, LLP's free portfolio monitoring service?(Required)
By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, LLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471

There is no cost or obligation to you.

What is Johnson Fistel investigating? Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.

In September of 2023, the company released details of its 12-week treatment of severe ulcerative colitis. The results demonstrated that 25.7% of patients who received their treatment showed improvement. Following this news, the stock plummeted 55%.

What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, LLP

501 W. Broadway, Suite 800, San Diego, CA 92101

James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471

jimb@johnsonfistel.com or fjohnson@johnsonfistel.com